TEL AVIV, Israel, May 7, 2020 /PRNewswire/ — Therapix Biosciences Ltd. (Nasdaq: TRPX) (the “Company”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announces today the appointment of Prof. Ari Shamiss (M.D., M.P.A.) to the Company’s Board of Directors.

Therapix Biosciences logo (PRNewsfoto/Therapix Biosciences)

Prof. Shamiss is the outgoing CEO of Assuta Medical Centers, the largest private hospital network in Israel, and consists of eight hospitals and medical centers. Prof. Shamiss was the Director of Sheba General Hospital at Tel Hashomer for 10 years ending in August 2016, and is a co-founder of Assuta Life Ventures (ALiVe), Prof. Shamiss, is also a board member and advisory at numerous high-tech companies, and is involved in numerous global business projects in healthcare technology and infrastructure.

Prof. Shamiss